Single Antiplatelet Therapy or No Therapy (Control)

DRUG3 trials

Sponsors

Boston Scientific Corporation, Uppsala University, OCEAN-SHD Study Group

Conditions

AspirinHigh Bleeding RiskLeft Atrial Appendage ClosureMyocardial Infarction Type 2Non-Antithrombotic TherapyNonvalvular Atrial FibrillationStroke

Phase 4

Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure

RecruitingNCT07125417

OCEAN-SHD Study GroupAspirin, High Bleeding Risk, Left Atrial Appendage Closure +2

Start: 2025-05-29End: 2030-03-31Target: 500Updated: 2025-08-15

Unknown Phase

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

CompletedNCT02928497

Boston Scientific CorporationStroke

Start: 2017-02-06End: 2025-09-23Updated: 2026-03-19

Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study

CompletedNCT06736353

Uppsala UniversityMyocardial Infarction Type 2

Start: 2010-09-03End: 2022-05-05Updated: 2025-03-19

Related Papers

Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond.

2019-10-319 citations